SCHEMBL4692302

SCHEMBL4692302

COc1ccc(-c2cnn3c(N)c(-c4ccc(F)cc4)c(CCl)nc23)cc1OC

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.55
MEN1 O00255 5/20 0.55
RAB9A P51151 5/20 0.55
NPC1 O15118 5/20 0.55
RXFP1 Q9HBX9 1/20 0.55
RET P07949 8/20 0.54
KIF5B P33176 8/20 0.54
KDR P35968 7/20 0.54
ETV6 P41212 5/20 0.54
CCDC6 Q16204 4/20 0.51
LCK P06239 3/20 0.51
CSF1R P07333 3/20 0.51
LYN P07948 3/20 0.51
PDGFRB P09619 3/20 0.51
FGR P09769 3/20 0.51
KIT P10721 3/20 0.51
SRC P12931 3/20 0.51
PDGFRA P16234 3/20 0.51
FGFR2 P21802 3/20 0.51
BLK P51451 3/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4695093 0.85 FYN (0.68) KMT2AMEN1RAB9ANPC1RET
SCHEMBL4695472 0.84 RET (0.54) KMT2AMEN1RAB9ANPC1RXFP1
SCHEMBL4695372 0.84 RET (0.55) KMT2AMEN1RAB9ANPC1RXFP1
SCHEMBL4171927 0.79 FYN (0.67) KMT2AMEN1RAB9ANPC1RXFP1
SCHEMBL27709380 0.77 RET (0.54) KMT2AMEN1RAB9ANPC1RXFP1
SCHEMBL4166019 0.76 NPC1 (0.60) KMT2AMEN1RAB9ANPC1RXFP1
SCHEMBL4171882 0.75 KMT2A (0.59) KMT2AMEN1RAB9ANPC1RXFP1
SCHEMBL4695452 0.72 FYN (0.60) KMT2AMEN1RAB9ANPC1RET
SCHEMBL4179850 0.72 FYN (0.71) KMT2AMEN1RAB9ANPC1RXFP1
SCHEMBL4167662 0.72 FYN (0.59) KMT2AMEN1RAB9ANPC1RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080234284-A1 Pyrazolo[1,5-a]Pyrimidin-7-Yl Amine Derivatives as Protein Kinase Inhibitors NOVARTIS AG (CH) 2008-09-25 US disclosed
EP-1910368-A1 PYRAZOLO[1.5-A]PYRIMIDIN-7-YL AMINE DERIVATIVES AS PROTEIN KINASE INHIBITORS Novartis AG (CH) 2008-04-16 EP disclosed
WO-2007009773-A1 PYRAZOLO[1.5-A]PYRIMIDIN-7-YL AMINE DERIVATIVES AS PROTEIN KINASE INHIBITORS NOVARTIS AG (CH) 2007-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234284-A1 Pyrazolo[1,5-a]Pyrimidin-7-Yl Amine Derivatives as Protein Kinase Inhibitors MAP3K5, MAP3K20, MAP3K7 KMT2A 1392/4885MEN1 2127/4885RAB9A 1184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.